DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B Stock

Certificat

DE000ME9ZQQ9

Real-time Bid/Ask 11:14:48 2024-07-03 EDT
124.67 EUR / 124.7 EUR -2.37% Intraday chart for DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B
Current month-0.78%
1 month+5.56%
Date Price Change
24-07-03 125.9 -1.39%
24-07-02 127.7 -1.41%
24-07-01 129.5 +0.64%
24-06-28 128.7 -0.05%
24-06-27 128.8 -0.25%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 09:19 am

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME9ZQQ
ISINDE000ME9ZQQ9
Date issued 2024-03-11
Cap 150 $
Last trading day 2024-09-20
Maturity 2024-09-20 (79 Days)
Parity 1 : 1
Emission price 118.9
Emission volume N/A
Payment day 2024-09-27
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 2.994 %
Sideways yield 3.103 %
Sideways yield pa 14.34 %
Outperformance point 154.6 $
Break even 134.65 €
Highest since issue 129.5
Lowest since issue 111.1
Spread 0.04
Spread %0.03%
Distance Cap -12.51 $
Distance Cap %-9.10%
Max. earning 14.21
Max. earning % 11.40 %

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5 DKK
Average target price
952.2 DKK
Spread / Average Target
-4.16%
Consensus